EFG Asset Management North America Corp. Has $5.82 Million Holdings in Vericel Co. (NASDAQ:VCEL)

EFG Asset Management North America Corp. boosted its position in shares of Vericel Co. (NASDAQ:VCEL - Free Report) by 83.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 106,064 shares of the biotechnology company's stock after acquiring an additional 48,295 shares during the period. EFG Asset Management North America Corp. owned approximately 0.21% of Vericel worth $5,819,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of VCEL. Arcadia Investment Management Corp MI bought a new stake in Vericel in the 4th quarter valued at $48,000. Smartleaf Asset Management LLC raised its position in Vericel by 511.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,265 shares of the biotechnology company's stock worth $70,000 after purchasing an additional 1,058 shares in the last quarter. Geneos Wealth Management Inc. boosted its holdings in Vericel by 826.6% during the fourth quarter. Geneos Wealth Management Inc. now owns 2,511 shares of the biotechnology company's stock valued at $138,000 after purchasing an additional 2,240 shares in the last quarter. Quantbot Technologies LP bought a new stake in shares of Vericel in the 3rd quarter valued at approximately $146,000. Finally, KBC Group NV raised its holdings in shares of Vericel by 82.5% in the 4th quarter. KBC Group NV now owns 2,707 shares of the biotechnology company's stock worth $149,000 after buying an additional 1,224 shares in the last quarter.

Insider Buying and Selling

In other news, CEO Dominick Colangelo sold 26,592 shares of Vericel stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $45.78, for a total transaction of $1,217,381.76. Following the completion of the sale, the chief executive officer now owns 259,997 shares of the company's stock, valued at approximately $11,902,662.66. This trade represents a 9.28 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Robert L. Md Zerbe sold 2,500 shares of the stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $62.50, for a total value of $156,250.00. Following the sale, the director now directly owns 26,595 shares in the company, valued at $1,662,187.50. This represents a 8.59 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 34,092 shares of company stock worth $1,683,582. Company insiders own 5.20% of the company's stock.

Remove Ads

Vericel Stock Down 3.4 %

Shares of NASDAQ:VCEL traded down $1.57 during midday trading on Friday, hitting $44.50. The stock had a trading volume of 298,050 shares, compared to its average volume of 377,899. The business's 50-day simple moving average is $53.23 and its 200-day simple moving average is $51.73. Vericel Co. has a 12 month low of $39.12 and a 12 month high of $63.00. The company has a market cap of $2.23 billion, a P/E ratio of 741.79 and a beta of 1.78.

Analyst Ratings Changes

Several research analysts have issued reports on VCEL shares. Stephens reiterated an "overweight" rating and set a $65.00 price objective on shares of Vericel in a research note on Wednesday, January 15th. StockNews.com raised shares of Vericel from a "sell" rating to a "hold" rating in a research note on Saturday, March 8th. Canaccord Genuity Group boosted their price objective on Vericel from $64.00 to $67.00 and gave the stock a "buy" rating in a research note on Monday, February 3rd. Truist Financial reiterated a "buy" rating and set a $61.00 price target (down previously from $67.00) on shares of Vericel in a research report on Monday, March 3rd. Finally, HC Wainwright restated a "buy" rating and issued a $60.00 price objective on shares of Vericel in a research report on Friday, February 28th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $62.29.

Vericel Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.